comparemela.com
  1. Home
  2. Live Updates
  3. PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy : comparemela.com

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Boston ,Massachusetts ,United States ,James Mcarthur ,Investor Contactlaurence Wattsgilmartin Group ,Linkedin ,Twitter ,Media Contactgwendolyn Schankerlifesci Communications ,Pepgen Inc ,Nasdaq ,Safety Review Committee ,Enhanced Delivery Oligonucleotide ,Tissue Concentration ,Exon Skipping Results ,Myotonic Dystrophy Type ,Private Securities Litigation Reform Act ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.